A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction

医学 心力衰竭 射血分数 内科学 地高辛 心脏病学 依瓦布拉定 缬沙坦 心率 血压
作者
Jasper Tromp,Wouter Ouwerkerk,Dirk J. van Veldhuisen,Hans L. Hillege,A. Mark Richards,Peter van der Meer,Inder Anand,Carolyn S.P. Lam,Adriaan A. Voors
出处
期刊:Jacc-Heart Failure [Elsevier]
卷期号:10 (2): 73-84 被引量:111
标识
DOI:10.1016/j.jchf.2021.09.004
摘要

This study sought to estimate and compare the aggregate treatment benefit of pharmacological therapy for heart failure (HF) with reduced ejection fraction.The estimated treatment effects of various combinations of contemporary HF medical therapies are not well characterized.We performed a systematic network meta-analysis, using MEDLINE/EMBASE and the Cochrane Central Register of Controlled Trials for randomized controlled trials published between January 1987 and January 2020. We included angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers (BB), mineralocorticoid receptor antagonists (MRAs), digoxin, hydralazine-isosorbide dinitrate, ivabradine, angiotensin receptor-neprilysin inhibitors (ARNi), sodium glucose cotransporter-2 inhibitors (SGLT2i), vericiguat, and omecamtiv-mecarbil. The primary outcome was all-cause death. We estimated the life-years gained in 2 HF populations (BIOSTAT-CHF [BIOlogy Study to TAilored Treatment in Chronic Heart Failure] and ASIAN-HF [Asian Sudden Cardiac Death in Heart Failure Registry]).We identified 75 relevant trials representing 95,444 participants. A combination of ARNi, BB, MRA, and SGLT2i was most effective in reducing all-cause death (HR: 0.39; 95% CI: 0.31-0.49); followed by ARNi, BB, MRA, and vericiguat (HR: 0.41; 95% CI: 0.32-0.53); and ARNi, BB, and MRA (HR: 0.44; 95% CI: 0.36-0.54). Results were similar for the composite outcome of cardiovascular death or first hospitalization for HF (HR: 0.36; 95% CI: 0.29-0.46 for ARNi, BB, MRA, and SGLT2i; HR: 0.44; 95% CI: 0.35-0.56 for ARNi, BB, MRA, and omecamtiv-mecarbil; and HR: 0.43; 95% CI: 0.34-0.55 for ARNi, BB, MRA, and vericiguat). The estimated additional number of life-years gained for a 70-year-old patient on ARNi, BB, MRA, and SGLT2i was 5.0 years (2.5-7.5 years) compared with no treatment in secondary analyses.In patients with HF with reduced ejection fraction, the estimated aggregate benefit is greatest for a combination of ARNi, BB, MRA, and SGLT2i.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
flysky120发布了新的文献求助30
3秒前
3秒前
mmlb完成签到,获得积分20
4秒前
吉祥财子完成签到,获得积分10
4秒前
yao完成签到,获得积分10
5秒前
6秒前
陈向琴发布了新的文献求助10
6秒前
科研小白发布了新的文献求助10
7秒前
xiying完成签到 ,获得积分10
7秒前
香锅不要辣完成签到 ,获得积分10
7秒前
科研通AI2S应助乐正念云采纳,获得30
8秒前
12秒前
隐形之玉发布了新的文献求助10
13秒前
默默的安白完成签到 ,获得积分10
14秒前
秋天的向日葵完成签到 ,获得积分10
15秒前
mmlb关注了科研通微信公众号
15秒前
16秒前
Junlei完成签到,获得积分10
16秒前
17秒前
茄子发布了新的文献求助10
17秒前
kento应助加菲丰丰采纳,获得150
20秒前
21秒前
21秒前
Roxanne发布了新的文献求助10
21秒前
干净翠桃发布了新的文献求助10
22秒前
22秒前
代小葵完成签到,获得积分20
23秒前
25秒前
繁荣的映雁完成签到,获得积分10
27秒前
28秒前
小蘑菇应助小云采纳,获得10
28秒前
温暖的颜演完成签到 ,获得积分10
29秒前
lihongchi发布了新的文献求助10
33秒前
33秒前
33秒前
33秒前
英俊的铭应助TY采纳,获得10
34秒前
走着走着就散了完成签到,获得积分10
34秒前
复杂真完成签到 ,获得积分10
36秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137638
求助须知:如何正确求助?哪些是违规求助? 2788565
关于积分的说明 7787590
捐赠科研通 2444902
什么是DOI,文献DOI怎么找? 1300139
科研通“疑难数据库(出版商)”最低求助积分说明 625814
版权声明 601023